Kazia Therapeutics Ltd
Kazia Therapeutics Ltd (ASX:KZA) is listed on the Australian Securities Exchange.
See more information about Kazia Therapeutics Ltd
Kazia Therapeutics shares surge after positive early phase II study results for GDC-0084 in brain cancer patients
Kazia Therapeutics Ltd (ASX:KZA (NASDAQ:KZIA) shares are trading about 53% higher intra-day after revealing positive interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of primary brain cancer.
Nine patients participated in Stage 1 of the study, of which eight were evaluable for efficacy.
Progression-free survival (PFS) in this initial group of patients was determined to be 8.4 months.
The existing standard of care, temozolomide, has a reported PFS of around 5.3 months, although cross-study comparisons must always be treated with caution.
Overall survival (OS) could not yet be calculated, with 75% of evaluable patients still alive at the cut-off date for analysis.
In aggregate, these early results provide a strong signal that GDC-0084 may provide clinical benefit in this patient population.
Other Kazia Therapeutics Ltd news
- Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
2020-09-22 - Kazia Therapeutics bringing a vetted drug class to the brain: Edison
2020-09-09 - Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
2020-08-24 - Kazia Therapeutics raises $1.8 million in well supported share placement
2020-05-06 - Kazia Therapeutics extends SPP owing to strong demand
2020-05-04
